Skip Navigation


European Heart Journal Advance Access originally published online on April 4, 2008
European Heart Journal 2008 29(9):1079-1081; doi:10.1093/eurheartj/ehn143
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/9/1079    most recent
ehn143v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Weber, M.
Right arrow Articles by Hamm, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, M.
Right arrow Articles by Hamm, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Novel biomarkers—the long march from bench to bedside

Michael Weber and Christian Hamm*

Kerckhoff Heart Center, Departement of Cardiology, Benekestraße 2–8, D-61231 Bad Nauheim, Germany

* Corresponding author. Tel: +49 6232 9960, Fax: +49 6232 9962313, Email: c.hamm@Kerckhoff-Klinik.de

This editorial refers to ‘Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18’{dagger} by D.A. Morrow et al., on page 1096

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

{dagger} doi:10.1093/eurheartj/ehn071 Back

The first 10% of the full text of this article appears below.

In recent years, a deeper understanding of the pathobiology of atherothrombosis as the underlying mechanism of acute coronary syndromes (ACS) has directed scientific studies towards the evaluation of novel serum biomarkers as potential diagnostic tools for the clinical setting. Prerequisites for a biomarker to enter clinical routine in ACS are several fold. The most important features are that the marker can be offered on a routine platform, provides higher sensitivity and specificity than the electrocardiogram in predicting outcome, and it should impact therapeutic decision making. Markers reflecting increased risk for coronary artery disease, such asserum . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
David A. Morrow, Marc S. Sabatine, Marie-Luise Brennan, James A. de Lemos, Sabina A. Murphy, Christian T. Ruff, Nader Rifai, Christopher P. Cannon, and Stanley L. Hazen
EHJ 2008 29: 1096-1102. [Abstract] [Full Text]